Brind.

Karyopharm Therapeutics shares lost 61.1% on August 12, 2025, compared to the S&P 500's gains.

2 reports, 2 independent Updated Aug 12
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Karyopharm Therapeutics shares lost 61.1% on August 12, 2025, compared to the S&P 500's gains.

Who's involved

What this event is mainly about
Karyopharm Therapeutics (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Karyopharm shares dropped 61.1% on Aug 12, 2025, compared to S&P 500 gains.1 source
  2. Karyopharm Therapeutics missed revenue expectations and saw declining revenue estimates.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $4.32 per share versus the Zacks Consensus Estimate of a loss o
  • GuruFocus.comKaryopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) is set to release its Q2 2025 earnings on Aug 11, 2025. The consensus esti